Braxia Scientific Appoints Dr. David Greenberg to Board of Directors
TORONTO, May 31, 2021 /PRNewswire/ – Braxia Scientific Corp. (the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce it has appointed Dr. David Greenberg to its Board of Directors.
A nationally recognized general medical practitioner for more than 30 years and a lecturer at The University of Toronto in the Department of Family and Community…
